Disparate Effects of Metabolically Healthy Obesity in Coronary Heart Disease and Heart Failure∗  by Lavie, Carl J. et al.
Journal of the American College of Cardiology Vol. 63, No. 11, 2014
 2014 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.10.080EDITORIAL COMMENTDisparate Effects of
Metabolically Healthy
Obesity in Coronary Heart
Disease and Heart Failure*Carl J. Lavie, MD,yz Richard V. Milani, MD,y
Hector O. Ventura, MDy
New Orleans and Baton Rouge, Louisiana
The conditions of being overweight or obese have been
increasing in epidemic proportions in the United States and
in much of the Westernized world. At present, more than
70% of the U.S. population is considered to be overweight
or obese (1). Even worse, the proportion of severe or morbid
obesity, also called “class III obesity” (body mass index
[BMI] 40 kg/m2), is increasing more so than obesity per
se, and now approximately 3% of the U.S. population meet
this level of obesity (2,3). Although welcome declines have
been noted in cardiovascular disease (CVD) mortality rates
in recent decades, concern has been expressed that the high
prevalence of obesity and especially morbid obesity may
reverse this trend (1).See page 1071There has been considerable debate on the importance of
obesity in U.S. and worldwide mortality levels. A recent
high-proﬁle publication by Masters et al. (4) suggested that
obesity contributes to approximately 20% of U.S. mortality.
In contrast, a large review from Flegal et al. (5) analyzed 97
studies of 2.9 million individuals, including >270,000
deaths, and demonstrated that optimal survival occurred in
“overweight” patients (BMI: 25 to 30 kg/m2), who had a
signiﬁcant 6% lower mortality than the “normal-weight”
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disclose.obesity group (class I to III combined) had an increased
mortality, the class I obese cohort (BMI: 30 to 35 kg/m2)
had a 5% lower mortality than the normal-weight BMI
cohort, which was almost statistically signiﬁcant.
Obesity adversely affects almost all of the major CVD risk
factors, including insulin sensitivity (leading to metabolic
syndrome and type 2 diabetes mellitus), blood pressure,
dyslipidemia, and systemic inﬂammation and leads to ab-
normalities in left ventricular geometry and systolic and
especially diastolic dysfunction (1,6). It is not surprising that
obesity increases the risk of almost all CVD, including
hypertension, coronary heart disease (CHD), heart failure
(HF), atrial ﬁbrillation, and peripheral arterial disease.
However, prior research has questioned whether obesity
without cardiometabolic abnormalities, or “metabolically
healthy obesity,” has adverse effects on overall CVD risk
(7–11). In this regard, prior research regarding both CHD
and HF has been conﬂicting.
In this issue of the Journal, Mørkedal et al. (7) assessed a
cohort of more than 60,000 people from Norway who were
free of CVD and assessed the risk of developing acute
myocardial infarction (AMI) and the ﬁrst HF. After
12 years of follow-up, they report a disparate impact of
obesity in the development of CHD and HF. For AMI, the
metabolically healthy obese cohort, unlike the metabolically
unhealthy cohort, did not seem to have an increased risk
of AMI, supporting the premise that the adverse effects
of obesity on CHD can be attributed to the adverse effects
that obesity has on the various cardiometabolic risk factors
and that any adverse effects beyond these metabolic abnor-
malities are minimal, if any. On the other hand, the impact
of obesity on HF is different.
As we have recently reviewed (6), increased adiposity
increases total blood volume, stroke volume, cardiac output,
and cardiac work and leads to signiﬁcant abnormalities on
both the right and left sides of the heart (Fig. 1). It is not
surprising that the risk of HF is signiﬁcantly increased in
obesity. This is probably best demonstrated in the analysis
of 5,661 subjects from the Framingham Heart Study, which
showed an increased prevalence of HF across the entire
spectrum of BMI, with a 5% increase in HF prevalence
in men and a 7% increase in HF prevalence in women for
every 1 kg/m2 increase in BMI (12). Other studies have
demonstrated that HF particularly increases with the dura-
tion of morbid obesity (13). The data in the present large
cohort from Norway support the impact of obesity, especially
more long-lasting and severe obesity, for increasing the
development of ﬁrst HF, and this impact of obesity in HF
appears regardless of the overall cardiometabolic status,
healthy or not. These data are in contrast to those reported
from a small cohort of 550 patients from Greece, which
suggested that metabolic syndrome was more related with
HF risk than obesity (14). However, the data from this
larger study seem more in line with the pathophysiology
of obesity, in which adipose tissue adversely affects the
cardiovascular status, including hemodynamic and cardiac
Figure 1 Pathophysiology of Obesity Cardiomyopathy
This diagram shows the central hemodynamic, cardiac structural abnormalities,
and alterations in ventricular function that may occur in severely obese patients
and predispose to heart failure (HF). Left ventricular (LV) hypertrophy in severe
obesity may be eccentric or concentric. In uncomplicated (normotensive) severe
obesity, eccentric LV hypertrophy predominates. In severely obese patients with
long-standing systemic hypertension, concentric LV hypertrophy is frequently
observed and may occur more commonly than eccentric LV hypertrophy. Whether
and to what extent metabolic disturbances, such as lipotoxicity, insulin resistance,
leptin resistance, and alterations of the renin-angiotensin-aldosterone system,
contribute to obesity cardiomyopathy in humans are uncertain. Adapted with
permission from Lavie et al. (6). LV ¼ left ventricular; RV ¼ right ventricular.
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1080structure and function, regardless of the underlying car-
diometabolic status (4,5).
Once CHD or HF becomes manifest, similar to other
cohorts with CVD, including hypertension and atrial
ﬁbrillation, an obesity paradox is apparent because over-
weight and obese subjects with these conditions seem to
have a better prognosis than their leaner counterparts
with the same diseases (1). This paradox is present in
overweight and obese patients with CHD, despite the fact
that obese patients have considerably more cardiometabolic
abnormalities, including elevated glucose, lipid, and
blood pressure levels, and more inﬂammation (15,16).
Prognosis in both CHD and HF is largely related to baseline
cardiorespiratory ﬁtness, with the ﬁtter patients having a
good prognosis and no obesity paradox, whereas the worst
prognosis is in the leanest patients who are unﬁt (17,18).
On the basis of these ﬁndings and other data, 4 major
factors should be emphasized. First, maintaining healthy
weight, cardiometabolic status, and overall ﬁtness wouldbe ideal for CVD prevention. Second, if substantial weight
gain occurs, preventing and treating cardiometabolic ab-
normalities seem merited. Third, unlike CHD, for which
maintaining a healthy cardiometabolic status seems to pro-
tect the obese patients from acute disease, in HF, the risk is
increased in obesity regardless of cardiometabolic status.
Fourth, overall cardiorespiratory ﬁtness, which may be the
strongest of the CVD risk factors, seems to be protective for
the overweight and obese patients with CHD or CVD.
Finally, measures to prevent being overweight or obese
should be emphasized and encouraged. By improving levels
of physical activity, and thus an individual’s level of ﬁtness,
one would prevent both CHD and HF and improve the
prognosis in these disorders. However, in our current soci-
ety, achieving this goal may involve a considerable amount
of wishful thinking.
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